EKF - Preliminary results, major acquisition and exclusive distribution agreement

Tuesday, May 24 2011 by

EKF Diagnostics, the point of care diagnostics company, announced a major acquisition and distribution agreement in the US alongside its preliminary results to 31st December 2010.

EKF has agreed to acquire Stanbio Laboratory L.P. for an initial consideration of $19.5 million, comprising $14 million in cash and the balance in shares. The deal also includes performance based deferred consideration of up to $6 million. This will be funded by a £13 million placing at 20p per share in exchange for shares representing 26% of the enlarged share capital.

Stanbio is a US based medical diagnostic devices distribution and manufacturing business. Its product range includes EKF's Hemo_Control device - its direct customers include Roche Diagnostics Corporation, Ortho Clinical Diagnostics, Cardinal Health Inc, Fisher Healthcare Inc and Sekisui Diagnostics LLC (formerly Genzyme Diagnostics). The company also sells through an extensive North and South American distributor network. For the year to December 2010, Stanbio achieved of sales of $16.3 million (2009: $15.2 million), adjusted EBITDA of $3.1 million (2009: $1.5 million) and pre-tax profit of $2.4 million (2009: $983,000).

In a related deal, Alere Inc has been appointed exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and the UK. The agreement is for an initial term of three years, and includes minimum sales levels designed to enable EKF to rapidly expand into an existing customer base. The agreement provides access to a large direct sales force in the US, and should enable EKF to significantly grow market share in the US haemoglobin testing market.

The final results to December 2010 showed sales of £6.5 million (2009: £nil), adjusted EBITDA of £804,000 (2009: £(386,000)) and pre-tax loss of £2.1 million (2009: £(568,000)) - the results include an exceptional charge of £1.9 million (2009: £207,000 charge). The company reported that year end net cash was £2.7 million


This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.

Do you like this Post?
0 thumbs up
0 thumbs down
Share this post with friends

EKF Diagnostics Holdings Plc designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other company products under separate distribution agreements. The Company operates in the United States, Germany, Poland, Russia, United Kingdom and Ireland. The Company is also a manufacture and distribution of organ injury biomarkers specializing in acute injury to kidneys (AKI), liver and pancreas. In March 2014, EKF Diagnostics Holdings PLC acquired Separation Technology Inc. more »

Share Price (AIM)
-4.4  -16.1%
P/E (fwd)
Yield (fwd)
Mkt Cap (£m)

  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »

What's your view on this thread? to Comment Now

You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter

Stock Picking Tutorial Centre

Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.

Get started
or Take a Tour to find out more.